GSK terminates collaboration on IDE275 and IDE705; programs returning to IDEAYA

IDEAYA Biosciences, Inc.

GSK gave written notice on Dec 9, 2025 to terminate the June 2020 Collaboration, Option and License Agreement.
Termination effective March 9, 2026; 90-day transition for GSK to transfer Werner Helicase (IDE275) and Pol Theta (IDE705) programs.
IDEAYA will evaluate strategic options for IDE275 and IDE705 in 2026.
Cash runway guidance into 2030 remains unchanged despite the termination.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IDEAYA Biosciences, Inc. terminated Collaboration, Option and License Agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited (effective 2025-12-09).

Action: termination
Agreement: collaboration
Counterparty: GlaxoSmithKline Intellectual Property (No. 4) Limited
Effective: 2025-12-09

Exact text from the filing

On December 9, 2025, GlaxoSmithKline Intellectual Property (No. 4) Limited ("GSK") delivered written notice to IDEAYA Biosciences, Inc. (the "Company") of its election to terminate the Collaboration, Option and License Agreement, dated June 15, 2020 (as amended, the "Agreement").

View on SEC.gov

Browse all material agreements →

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-317541

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.